Pharmacokinetics of (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt and (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu administered intravenously to beagle dogs. 1993

T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
Tsukuba Research Laboratories, Eisai Company, Ltd., Ibaraki, Japan.

The pharmacokinetics of two analogues (NT-1 and NT-2) of the smallest active fragment of neurotensin were investigated in beagle dogs after intravenous (iv) administration at the doses of 0.1 and 0.5 mg/kg for NT-1 and of 0.25 and 0.5 mg/kg for NT-2. After iv administration of these two drugs, the plasma levels decreased with time with a biexponential pattern, and linear kinetic behavior was observed. The pharmacokinetic parameters (mean +/- standard error of mean) after iv administration of NT-1 at 0.1 mg/kg were as follows: the half-life of the distribution phase (t1/2 alpha) was 0.29 +/- 0.11 h, the half-life of the terminal phase (t1/2 beta) was 1.99 +/- 0.41 h, total plasma clearance (CL) was 33.2 +/- 6.3 mL/h/kg, steady-state volume of distribution (Vdss) was 57.1 +/- 2.8 mL/kg, and mean residence time (MRT) was 2.20 +/- 0.55 h. The t1/2 alpha, t1/2 beta, CL, Vdss, and MRT values after iv administration of NT-2 at 0.25 mg/kg were 0.11 +/- 0.02 h, 0.58 +/- 0.04 h, 257.3 +/- 17.2 mL/h/kg, 180.3 +/- 4.6 mL/kg, and 0.71 +/- 0.04 h, respectively. After iv administration of NT-1, NT-2 was detected in the plasma. It was confirmed from this result that NT-1 was metabolically hydrolyzed to NT-2 in the body of beagle dog.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009496 Neurotensin A biologically active tridecapeptide isolated from the hypothalamus. It has been shown to induce hypotension in the rat, to stimulate contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duodenum. There is also evidence that it acts as both a peripheral and a central nervous system neurotransmitter.
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002627 Chemistry, Physical The study of CHEMICAL PHENOMENA and processes in terms of the underlying PHYSICAL PHENOMENA and processes. Physical Chemistry,Chemistries, Physical,Physical Chemistries
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog

Related Publications

T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
April 1978, Journal of pharmaceutical sciences,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
May 2014, Doklady. Biochemistry and biophysics,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
August 2023, Journal of agricultural and food chemistry,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
April 1992, The Journal of antimicrobial chemotherapy,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
August 1999, Journal of veterinary pharmacology and therapeutics,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
July 1983, International journal of peptide and protein research,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
July 2011, Journal of cardiovascular pharmacology,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
December 2017, Bulletin of experimental biology and medicine,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
May 1983, European journal of pharmacology,
T Tokumura, and R Machida, and Y Tsuchiya, and A Sasaki, and K Abe, and T Tanaka, and Y Saeki
May 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Copied contents to your clipboard!